H. Debiec, V. Guigonis, B. Mougenot, F. Decobert, J. P. Haymann et al., Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase, J Am Soc Nephrol, vol.25, pp.675-680, 2014.

, Allo-Immune Membranous Nephropathy and Replacement Therapy antibodies, N Engl J Med, vol.346, pp.2053-2060, 2002.

H. Debiec, J. Nauta, F. Coulet, M. Van-der-burg, V. Guigonis et al., Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies, Lancet, vol.364, pp.1252-1259, 2004.

B. G. Hudson, The molecular basis of Goodpasture and Alport syndromes: Beacons for the discovery of the collagen IV family, J Am Soc Nephrol, vol.15, pp.2514-2527, 2004.

J. Patrakka, V. Ruotsalainen, P. Reponen, E. Qvist, J. Laine et al., Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: Role of nephrin, Transplantation, vol.73, pp.394-403, 2002.

S. M. Richards, Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders, Clin Appl Immunol Rev, vol.2, pp.241-253, 2002.

D. A. Brooks, Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models, Mol Genet Metab, vol.68, pp.268-275, 1999.

E. Koren and L. A. Zuckerman, Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction, Curr Pharm Biotechnol, vol.3, pp.349-360, 2002.

T. E. Hunley, D. Corzo, M. Dudek, P. Kishnani, A. Amalfitano et al., Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease, Pediatrics, vol.114, pp.532-535, 2004.

B. Winchester, A. Vellodi, and E. Young, The molecular basis of lysosomal storage diseases and their treatment, Biochem Soc Trans, vol.28, pp.150-154, 2000.

V. Valayannopoulos, H. Nicely, P. Harmatz, S. Turbeville, and V. I. Mucopolysaccharidosis, Orphanet J Rare Dis, vol.5, 2010.

F. J. Dixon, J. D. Feldman, and J. J. Vazquez, Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis, J Exp Med, vol.113, pp.899-920, 1961.

R. J. Glassock, Human idiopathic membranous nephropathy-a mystery solved?, N Engl J Med, vol.361, pp.81-83, 2009.

P. Ronco and H. Debiec, Pathogenesis of membranous nephropathy: Recent advances and future challenges, Nat Rev Nephrol, vol.8, pp.203-213, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00919135

L. H. Beck, R. G. Bonegio, G. Lambeau, D. M. Beck, D. W. Powell et al., M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, N Engl J Med, vol.361, pp.11-21, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00417718

H. Debiec, F. Lefeu, M. J. Kemper, P. Niaudet, G. Deschênes et al., Early-childhood membranous nephropathy due to cationic bovine serum albumin, N Engl J Med, vol.364, pp.2101-2110, 2011.

P. Harmatz, R. Giugliani, I. Schwartz, N. Guffon, E. L. Teles et al.,

, Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study, MPS VI Phase 3 Study Group, vol.148, pp.533-539, 2006.

C. J. Hendriksz, R. Giugliani, P. Harmatz, C. Lampe, A. M. Martins et al., Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP), J Inherit Metab Dis, vol.36, pp.373-384, 2013.

L. Giardino, S. Armelloni, A. Corbelli, D. Mattinzoli, C. Zennaro et al., Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier, J Am Soc Nephrol, vol.20, 1929.

T. Namba, T. M. Ishii, M. Ikeda, T. Hisano, T. Itoh et al., Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics, Eur J Pharmacol, vol.395, pp.95-101, 2000.

M. J. Morton, K. Hutchinson, P. W. Mathieson, I. R. Witherden, M. A. Saleem et al., Human podocytes possess a stretch-sensitive, Ca2 +-activated K+ channel: Potential implications for the control of glomerular filtration, J Am Soc Nephrol, vol.15, pp.2981-2987, 2004.

P. S. Kishnani, M. Nicolino, T. Voit, R. C. Rogers, A. C. Tsai et al., Chinese hamster ovary cell-derived recombinant human acid alphaglucosidase in infantile-onset Pompe disease, J Pediatr, vol.149, pp.89-97, 2006.

M. Rosenberg, W. Kingma, M. A. Fitzpatrick, and S. M. Richards, Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration, Blood, vol.93, pp.2081-2088, 1999.

J. Wang, J. Lozier, G. Johnson, S. Kirshner, D. Verthelyi et al., Neutralizing antibodies to therapeutic enzymes: Considerations for testing, prevention and treatment, Nat Biotechnol, vol.26, pp.901-908, 2008.

H. Debiec, M. Hanoy, A. Francois, D. Guerrot, S. Ferlicot et al., Recurrent membranous nephropathy in an allograft caused by IgG3k targeting the PLA2 receptor, J Am Soc Nephrol, vol.23, pp.1949-1954, 2012.

/. Asn, , 2013030290.